# Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

> **NCT01355705** · PHASE1,PHASE2 · COMPLETED · sponsor: **Michaela Liedtke** · enrollment: 14 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Amrubicin
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Aspirin
- **DRUG:** Pegfilgrastim

## Key facts

- **NCT ID:** NCT01355705
- **Lead sponsor:** Michaela Liedtke
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2016-07
- **Final completion:** 2017-07
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2018-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01355705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01355705, "Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01355705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*